Former CMO Aurora BioPharma Currently at Celyad

Bikash is a physician-scientist trained in immunology and immuno-oncology with over two decades of experience in clinical research and development both in biotech industry and academia. Prior to joining Aurora, he worked as medical director at GSK and Novartis managing over twenty trials in immunology encompassing over ten thousand subjects across more than a hundred clinical trial sites in US and abroad leading to successful licensure of several products. Prior to joining the biotech industry, he worked at Harvard Medical School as medical director, faculty and scientist; and in public health and clinical care as an Epidemiologist through Massachusetts Department of Public Health on Centers of Disease Control (CDC) surveillance projects and at International Health Organization as its Chief Medical Officer. Bikash holds MD, DVM, MS and MVSc degress and post-doctoral trainings which he completed at University of Massachusetts Medical School and its affiliated hospitals, University of Illinois, S Illinois University, Birsa University, International School of Medicine, and Tufts University.


Patrick Wen is Director of the Center For Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. Dr. Wen is also chair of the Dana-Farber/Harvard Cancer Center Neuro-Oncology Clinical Trials Committee and principal or co-investigator of many ongoing clinical protocols. Dr. Wen's clinical research focuses on targeted molecular therapies and anti-angiogenic therapies for gliomas, meningiomas, and brain metastases. He serves on numerous national and international committees, including the NCI Developmental Therapeutics and the Cancer Diagnostic and Treatment SBIR Study Sections and co-chairs the American Brain Tumor Consortium New Agents Committees. He is Editor-in-Chief for the Journal of Neuro-Oncology and on the editorial board of Clinical Cancer Research. He is Chair of the Medical Advisory Board for the National Brain Tumor Society.


Kevin Krenitsky is a corporate strategist, and turnaround expert with significant experience growing and transforming venture-capital startup, privately held, and publicly traded organizations. Dr. Krenitsky has served as President at OpGen. At Foundation Medicine, Dr. Krenitsky was influential in taking the company from start-up to a $1 billion IPO in 2 years and later a 1.2B strategic investment by Roche. Dr. Krenitsky was also responsible for leading one of the most successful commercial launches (FoundationOne™) in the history of molecular diagnostics. Dr. Krenitsky has achieved a Doctor of Medicine degree from Jefferson Medical College in Philadelphia, PA, a Bachelor of Science degree in Business Management from the University of Scranton, PA, and is a Licensed Medical Doctor in the Commonwealth of Pennsylvania & Massachusetts.

Marc Lippman, M.D.

Marc is the Kathleen and Stanley Glaser Professor of Medicine and Deputy Director of the University of Miami Sylvester Comprehensive Cancer Center. Previously, from February 2001 to May 2007 he served as the John G. Searle Professor and Chairman of the Department of Internal Medicine at the University of Michigan School of Medicine. Previously, Dr. Lippman was the Director of the Lombardi Cancer Research Center from July 1988 to February 2001, Professor and Chairman of the Department of Oncology from July 1999 to February 2001 and Professor of Medicine at Georgetown University Medical School in Washington, D.C. from July 1988 to February 2001. He also served as Chief of the Division of Hematology-Oncology at Georgetown University Medical School from July 1995 to February 2001. He was Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute from July 1976 to July 1988. Dr. Lippman has authored over 500 peer- reviewed publications.

Richard Berman,MBA
Richard Berman is a member of the Board of Directors. Mr. Berman’s business career spans over 35 years of venture capital, senior management and merger and acquisitions experience. In the past five years, Mr. Berman has served as a director and/or officer of over a dozen public and private companies. From 2006 to 2011, he was Chairman of National Investment Managers, a company with $12 billion in pension administration assets. From 1998 to 2012, Mr. Berman served as a Director of Easy Link Int’l. Mr. Berman is currently a director of four public companies: Advaxis, Inc., Neostem, Inc., Cryoport, Inc. and Lustros, Inc. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; created the largest battery company in the world in the 1980s by merging Prestolite, General Battery and Exide to form Exide Technologies (XIDE); and advised on over $4 billion of M&A transactions (completed over 300 deals). He is a past Director of the Stern School of Business of NYU where he obtained his Bachelor of Science and Master of Business Administration. He also has U.S. and foreign law degrees from Boston College and The Hague Academy of International Law.